In a strategic move to strengthen its position in the sickle cell disease market, Novo Nordisk has partnered with IMMvention Therapeutix, Inc. to co-develop innovative oral treatments. This collaboration focuses on BACH1 inhibitors, which promise to induce fetal hemoglobin expression to treat sickle cell disease and other chronic conditions. The deal follows Novo’s significant presence in the field established by their $1.1 billion acquisition of Forma Therapeutics in 2022.
IMMvention brings to the table a unique approach with their BACH1 inhibitors, claiming superior druglike properties compared to competitors’ molecules. While specific timelines for clinical data remain unclear, IMMvention’s roadmap suggests IND-enabling studies and phase 1 trials will begin in 2026-2027. Under the agreement, Novo Nordisk will take the lead on development upon candidate nomination, while IMMvention retains rights to brain-penetrant BACH1 inhibitors for neurological conditions.
At OxyDial, we’re excited by Novo Nordisk’s commitment to expanding its rare disease portfolio. The combination of Novo’s development expertise and IMMvention’s innovative BACH1 inhibitor technology might be representing a significant advancement in the field.
Read more: https://lnkd.in/eRu-tNyP
#NovoDeal #SickleCell #BiotechInnovation #RareDiseases #DrugDevelopment #BACH1inhibitor #BiotechCollaboration #InnovationInHealthCare #PublicHealth #SCDInitiative